NCT04796012: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 6 Years to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with brain metastasis affecting the brainstem, midbrain, pons, or cerebellum, or within 10 mm of optic nerve; Patients with a history of leptomeningeal disease; Patients with prior treatment of CD137 agonists or immune checkpoint blockade therapies to include all anti-PD-1, and anti-PD-L1 therapeutic antibodies (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)

Comments are closed.

Up ↑